Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TT-034 in Chronic Hepatitis C
NCT01899092Phase 2Completed
- Sponsor
- Tacere Therapeutics
- Start
- Jan 2014
- Primary completion
- Sep 2016
- Modality
- Gene Editing, Viral Vectors, Viral-delivered RNAi
- Countries
- 1
01
Overview
A Phase 2 trial of TT-034 in hepatitis C (HCV), sponsored by Tacere Therapeutics. Started Jan 2014; status: completed.
02
Drugs
TT-034
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01899092.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01899092.